Mozobil: Phase II data

Data from the Phase II (Study 2101) trial in 25 multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients showed that Mozobil plus G-CSF caused 100% of the patients to collect enough cells for t...